TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
GILD

Gilead Sciences Inc

Healthcare · Drug Manufacturers - General

150.60$ +0.3% vs. previous close Closing price · As of: Sep 21, 2026

Statements

Ratios

Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.

Tick rows to compare them in a chart (up to 4)

Ratios GILD
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
Valuation
16.0 18.0 188.9 81.5 834.0 242.4 23.7 22.1 17.2 18.1 19.0
3.4 3.8 3.3 3.1 3.7 4.0 4.9 4.8 4.8 5.2 5.9 5.2
4.2 4.5 5.2 4.7 5.7 6.0 7.4 7.1 6.5 6.8 7.4 13.3
4.1 4.5 4.1 3.8 4.4 4.6 5.5 5.5 5.4 5.8 6.4 5.9
10.6 11.5 23.4 20.2 31.5 30.0 14.9 14.5 11.5 12.6 13.1 162.9
12.0 13.7 11.6 12.4 11.1 11.3 14.3 14.9 15.2 16.3 17.1 11.9
8.3% 7.3% 8.6% 8.0% 9.0% 8.9% 7.0% 6.7% 6.6% 6.1% 5.9% 8.4%
Margins
78.8% 76.0% 75.8% 75.7% 76.1% 78.3% 78.3% 78.5% 78.7% 78.8% 79.4% 79.6%
30.2% 28.0% 5.7% 9.2% 2.9% 5.8% 28.6% 27.9% 36.1% 37.5% 38.6% -4.6%
21.4% 20.9% 1.8% 3.8% 0.4% 1.7% 20.8% 21.9% 27.9% 28.9% 31.0% -10.6%
28.7% 27.4% 28.8% 24.8% 33.3% 35.8% 34.3% 32.5% 31.5% 32.1% 34.4% 43.3%
Returns
26.3% 24.8% 2.8% 5.8% 0.7% 2.5% 31.1% 32.1% 37.7% 37.5% 39.2% -27.4%
9.4% 9.1% 0.9% 2.0% 0.2% 0.8% 10.6% 11.3% 13.9% 14.4% 16.4% -6.6%
Balance Sheet & Debt
19,277 19,027 20,476 20,578 18,212 16,833 17,026 19,802 17,611 17,372 14,546 23,067
1.8 1.8 4.3 3.9 4.6 3.8 1.6 1.8 1.3 1.3 1.0 20.9
35.8% 36.8% 31.2% 34.1% 33.9% 32.8% 34.0% 35.3% 36.8% 38.5% 41.8% 24.0%
1.1 1.1 1.4 1.3 1.3 1.4 1.3 1.3 1.2 1.1 0.9 2.2
Per Share
4.67 4.51 0.39 0.84 0.10 0.38 4.74 5.03 6.47 6.79 7.35 -2.61
21.79 21.59 22.01 22.22 22.57 22.84 22.82 23.00 23.19 23.50 23.71 24.50
17.75 18.18 14.06 14.61 14.73 15.35 15.22 15.68 17.18 18.12 18.75 9.52
6.25 5.91 6.33 5.51 7.52 8.19 7.82 7.47 7.31 7.55 8.16 10.62

Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?